Stock Performance and Market Context
On 23 March 2026, Vivanza Biosciences Ltd’s stock price touched ₹1.82, its lowest level in the past year, representing a day decline of 4.71%. This fall was sharper than the Pharmaceuticals & Biotechnology sector’s decline of 3.84% on the same day. The stock also underperformed its sector by 0.87% on the day, trading below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
The broader market environment was challenging, with the Sensex opening sharply lower by 800.38 points and closing down 1,133.89 points at 72,598.69, a 2.6% decline. The Sensex itself was nearing its 52-week low of 71,425.01, trading 1.62% above that level and continuing a three-week losing streak with an 8.01% drop over that period. The index was also trading below its 50-day moving average, which itself was below the 200-day moving average, indicating a bearish trend.
Financial and Operational Indicators
Vivanza Biosciences Ltd is classified as a micro-cap company within the Pharmaceuticals & Biotechnology sector. Its market sentiment has deteriorated, reflected in a downgrade from a 'Sell' to a 'Strong Sell' rating by MarketsMOJO on 2 March 2026, with a Mojo Score of 29.0. This rating reflects concerns over the company’s long-term financial strength and profitability metrics.
Over the last five years, the company’s operating profits have declined at a compound annual growth rate (CAGR) of -4.85%, indicating weakening earnings capacity. The company’s ability to service debt is limited, with a high Debt to EBITDA ratio of 5.05 times, suggesting elevated leverage relative to earnings before interest, taxes, depreciation, and amortisation. Return on Equity (ROE) averaged 9.70%, a modest figure that points to relatively low profitability per unit of shareholder funds.
In terms of recent financial performance, the company reported net sales of ₹109.55 crores for the nine months ended December 2025, representing a substantial growth of 1,478.53% compared to the previous period. Profit after tax (PAT) for the same period was ₹0.85 crore, indicating a positive but modest profit level. Despite this, the company’s Return on Capital Employed (ROCE) was negative at -0.6%, reflecting challenges in generating returns from its capital base.
Comparative Performance and Valuation
Vivanza Biosciences Ltd’s stock has underperformed the broader market over the past year, delivering a total return of -15.35% compared to the Sensex’s -5.60% and the BSE500’s -3.45%. This relative underperformance highlights the stock’s vulnerability amid sector and market pressures.
The stock’s 52-week high was ₹2.94, indicating a decline of approximately 38% from that peak to the current 52-week low. Despite the negative price trend, the company’s valuation metrics suggest it is trading at a discount relative to its peers’ historical averages, with an enterprise value to capital employed ratio of 1.2. This valuation reflects the market’s cautious stance given the company’s financial profile and recent performance.
Technical Indicators
Technical analysis of Vivanza Biosciences Ltd’s stock reveals predominantly bearish signals. The Moving Average Convergence Divergence (MACD) indicator is bearish on a weekly basis, though mildly bullish on a monthly timeframe. The Relative Strength Index (RSI) does not currently signal any clear momentum on either weekly or monthly charts. Bollinger Bands indicate bearish trends on both weekly and monthly periods, while the Know Sure Thing (KST) indicator is bearish weekly but mildly bullish monthly. Dow Theory analysis shows no clear trend weekly and a mildly bearish stance monthly. Overall, daily moving averages remain bearish, reinforcing the downward price pressure.
Shareholding and Market Position
The majority of Vivanza Biosciences Ltd’s shares are held by non-institutional investors, which may contribute to higher volatility and less stable trading patterns. The company’s micro-cap status and relatively low market capitalisation further accentuate its sensitivity to market fluctuations and sector dynamics.
Summary of Key Metrics
To summarise, Vivanza Biosciences Ltd’s key financial and market metrics as of 23 March 2026 are:
- 52-week low price: ₹1.82
- Day change: -4.71%
- Mojo Score: 29.0 (Strong Sell rating)
- Debt to EBITDA ratio: 5.05 times
- Operating profit CAGR (5 years): -4.85%
- Return on Equity (average): 9.70%
- Net sales (9 months ended Dec 2025): ₹109.55 crores (growth of 1,478.53%)
- Profit after tax (9 months ended Dec 2025): ₹0.85 crore
- Return on Capital Employed: -0.6%
- Enterprise value to capital employed: 1.2
- 1-year stock return: -15.35%
- Sensex 1-year return: -5.60%
These figures illustrate the challenges faced by Vivanza Biosciences Ltd in maintaining profitability and market valuation amid a difficult sector and broader market environment.
